448 results about "Compound s" patented technology

Disclosed herein is a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof. Also disclosed herein are methods of treating a bacterial with a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof in combination with ceftibuten.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The application discloses a LYTAG-Gem compound for enhancing the anti-tumor effect of gemcitabine and application thereof, relates to the technical field of biological medicine, and particularly relates to a gemcitabine (Gem) targeted delivery system based on a lysosome targeting chimera (LYTAC) and application thereof in enhancing the anti-tumor process. 2+ The system is assembled from heavy chain ferritin, Ni 2+ , NTA-PEG5000-DBCO and a targeting ligand TPP-1-N3 in a specific mass percentage, can efficiently load Gem and form a nano compound with a particle size of about 59-79 nm, the system targets tumor cells through heavy chain ferritin, and realizes site-specific release of Gem in cells by means of an endocytosis-lysosome pathway mediated by the LYTAC structure, in-vivo pharmacodynamic experiments show that the LYTAC-Gem compound can significantly inhibit the tumor growth of a KPC pancreatic cancer mouse model, molecular mechanism research further reveals that the LYTAC-Gem compound can down-regulate the expression of PD-L1 protein in tumor tissues, and it is indicated that the LYTAC-Gem compound has the potential to activate an anti-tumor immune response, and the application provides a novel targeted delivery strategy for overcoming the toxic side effects and tumor drug resistance of gemcitabine.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The application belongs to the technical field of antitumor drugs, and particularly relates to an AuNRs@L / D-Ag2S QDs complex, a preparation method and application thereof. Sodium polystyrene sulfonate is electrostatically adsorbed on AuNRs to obtain 1-PSS-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 1-PSS-AuNRs to obtain 2-PAH-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 2-PAH-AuNRs to obtain a non-chiral nanomaterial; and the non-chiral nanomaterial is covalently crosslinked with L / D-Ag2S QDs to obtain the AuNRs@L / D-Ag2S QDs complex. The application combines the efficient photo-thermal conversion characteristics of AuNRs with the chiral-dependent targeting and potential fluorescence imaging ability of chiral Ag2S quantum dots by constructing a complex structure, so that a novel nanodiagnostic and therapeutic agent with efficient photo-thermal performance and chiral selectivity is obtained.

The application provides a self-driven BCG-nanoparticle complex and a preparation method thereof, and belongs to the fields of biological medicine and nanomaterials. The complex is a composite of BCG and cerium oxide nanoparticles with urease activity, the cerium oxide nanoparticles are coupled to the surface of the BCG in an asymmetric distribution through modified polyethyleneimine, and specifically, the surface of the BCG is connected to several modified polyethyleneimine derivatives through chemical bonds and electrostatic adsorption, and the polyethyleneimine derivatives wrap the cerium oxide nanoparticles through electrostatic adsorption. The complex can be self-driven by using the gas release and ion concentration change caused by the catalytic decomposition of urea in the environment, significantly enhances the adhesion and retention of BCG on the bladder wall, effectively overcomes the defects of low delivery efficiency and insufficient immune activation of traditional BCG therapy, simultaneously improves the tumor immune microenvironment, and can be used for preparing high-efficiency and low-toxicity bladder cancer treatment drugs.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application belongs to the technical field of anti-aging skin care product preparation, and discloses a composition containing a composite exosome-polypeptide, a preparation method thereof and application of the composition in cosmetics. The composition contains, in terms of mass fraction, 3.0%-7.0% of an exosome-polypeptide composite wrapped by a biomimetic liposome, 4%-9% of a plant active synergistic extract, 15%-20% of a temperature-sensitive moisturizing sustained-release system, 3%-6% of a lipid barrier repair agent, 0.3%-0.8% of an antioxidant stabilizer, and the rest is a basic base; the exosome is composed of membrane pod huangqi root exosome, salvia miltiorrhiza exosome and long life flower exosome; the polypeptide is composed of palmitoyl tripeptide-5 and acetyl hexapeptide-8; and the biomimetic liposome is composed of phosphatidylcholine, ceramide NP and phytosteryl oleate. The application is compounded by the composite exosome-polypeptide-multiple effect component, hierarchical synergy is achieved, multiple-dimensional aging targets are covered, the transdermal rate is improved, the activity is retained for a long time, the barrier repair and skin quality adaptation are considered, and the anti-aging performance is excellent.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

This invention discloses an amphoteric compound or its pharmaceutically acceptable salt, complex and its applications, wherein the amphoteric compound has a general structural formula as shown in formula (I); the amphoteric compound or its pharmaceutically acceptable salt of this invention can be used to prepare lipid nanoparticles for drug delivery, and the lipid nanoparticle delivery system has higher transfection efficiency, better delivery efficiency and better mRNA encapsulation rate compared with commercially available delivery systems.

The present invention relates to the use of a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for the preparation of a drug for the treatment of patients with active tuberculosis.

This invention relates to the field of pharmaceutical technology, and discloses a stress particle targeted degrader, its preparation method, and its applications. The compounds provided by this invention include ternary complexes composed of stress particle protein, a linker group, and an E3 ubiquitin ligand, or ternary complexes composed of stress particle protein, a linker group, and a ribonuclease L ligand. Compounds with different ligands exhibit good targeting and degradation effects on stress particles and can be used as stress particle targeted degraders in the preparation of antitumor drugs and anti-neurodegenerative disease drugs, showing promising application prospects in treating stress particle-induced tumor drug resistance and neurodegenerative diseases.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The application belongs to the field of food processing and biomedical technology, and discloses a preparation method of a salty taste enhancing peptide-naringenin compound and application of the compound in improving cognitive decline. The compound is prepared by compounding salty taste enhancing peptides from soft-shelled turtle eggs and naringenin at a ratio of 20-150:1 (w:w). The preparation process comprises the following steps: soft-shelled turtle egg enzymolysis, ultrafiltration, freeze-drying to obtain salty taste enhancing peptides, mixing the salty taste enhancing peptides with a naringenin solution, concentration, and freeze-drying. The compound has good stability, salty taste enhancing and antioxidant activities, can reduce the use of salt and maintain salty taste. The compound can improve cognitive decline and anxiety caused by aging and diabetes, improve autonomous activity, memory and social skills, strengthen physical fitness, protect nerve cells and skeletal muscles, maintain brain tissue health, and can be applied to the preparation of related preparations for improving cognitive decline.

This invention discloses a Tibetan bath composition compound and its preparation method, relating to the field of daily chemical products technology. The Tibetan bath composition compound consists of a ternary complex of scutellaria baicalensis hydroxypropyl-β-cyclodextrin nanoshell powder, Bacillus subtilis, Tibetan medicine composition, starch, anhydrous citric acid, sodium bicarbonate, calcium citrate, crospovidone, and magnesium stearate. Bacillus subtilis is used to ferment the ternary complex of scutellaria baicalensis hydroxypropyl-β-cyclodextrin nanoshell powder to obtain a fermentation-modified porous carrier, which is then loaded with the Tibetan medicine composition to form a Tibetan medicine inclusion powder. This not only achieves efficient drug delivery through a triple mechanism of biomodification, metabolite synergy, and structural optimization, but also forms a quaternary system with Terminalia chebula. The effervescent effect also enhances the penetration of Tibetan medicine components, which is beneficial for better exerting the antibacterial and anti-inflammatory effects of active substances, and significantly improving fungal infections and eczema-related skin problems.

The present application relates to a kind of self-setting composite bone implants based on gallic acid complex salt and preparation method thereof, belong to bone repair material field.The present application is specifically related to a kind of self-setting composite bone implants, it is characterized in that, component A, component B and component C, the component A is gallic acid and the complex salt of at least two metal elements, wherein the at least two metal elements are the metal element of promoting bone tissue regeneration or the trace metal element required by human body, and the at least two metal elements include calcium, the component B is the complex of calcium / strontium chondroitin sulfate and calcium sulfate, and the component C is magnesium calcium hydrogen phosphate complex.The self-setting composite bone implant of the present application has the characteristics of antibacterial, anti-inflammatory, promoting osteogenesis, instant shaping and all degradation, can meet the clinical needs of bone tumor, bone injury and the like, has wide application prospect in various bone repair, reconstruction and replacement.

The application belongs to the field of biological medicine, and discloses a drug screening method for promoting tumor neoantigen production. The method comprises the following steps: under the condition of immune activation, a to-be-screened compound is applied to a neoantigen generation defect cell model; indexes such as the expression level of the neoantigen or the neoantigen-MHC complex, the immune checkpoint molecule, the survival state or cytotoxicity of tumor cells, the activation or proliferation ability of immune cells, and the like are detected; and the candidate compound is comprehensively evaluated. The method realizes a three-dimensional integrated evaluation system of "neoantigen induction efficiency-tumor cytotoxicity characteristics-T cell immune activity" for the first time, can high-throughput screen a large-scale compound library, specifically recognizes and evaluates the comprehensive effect of the candidate compound, thereby efficiently discovers a lead drug with the activity of promoting tumor neoantigen production, solves the fundamental defect that the existing screening technology cannot target the evaluation of the neoantigen induction capacity, and provides a universal and expandable screening platform for the development of an immunotherapy sensitizer.

The present invention belongs to the technical field of sensorineural hearing. Provided is the use of SPTBN1 as a target in the treatment of GJB2-related sensorineural hearing loss. The use comprises: the construction of a stably transfected cell line, wherein: HEK293T cells are cultured using a DMEM culture medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37ºC with 95% air and 5% CO2, and when the cells reach 80%-90% confluence, cell passage is performed; IP-MS analysis, wherein: protein complexes are purified using Protein A / G immunoprecipitation magnetic beads, a portion of the extracted proteins is used as input, and then 2 μg of anti-Cx26 antibody is added to the remaining protein extract, same are gently pipetted and mixed, and incubated on a rotating shaker at 4℃ overnight; immunofluorescence observation of the co-localization of Cx26 and SPTBN1, wherein: a stably transfected cell line expressing WT-Cx26 and Mut-Cx26 is constructed; and co-immunoprecipitation (Co-IP) validation, wherein: a stably transfected cell line expressing WT-Cx26 is constructed. The present invention overcomes the limitations of therapeutic methods, such as the relatively low targeting specificity and short therapeutic time windows associated with full-length protein supplementation via gene therapy, thereby providing new insight into GJB2-related hearing loss, and a new target and a new treatment for same.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

Disclosed in the present invention is a phosphatidylserine and docosahexaenoic acid (DHA) composite, and its application thereof in a functional preparation, belonging to the field of health-care food. By combining two substances in a specific ratio and further applying them to edible functional preparations, brain entry efficiency of unsaturated fatty acids including DHA is improved. The ratio verifies a synergistic interaction mechanism of two active ingredients. Phosphatidylserine promotes enrichment of fatty acids such as the DHA in a brain by enhancing permeability of a blood-brain barrier, promotes neurogenesis, and enhances learning and memory abilities. Moreover, combination of the phosphatidylserine (PS) and the DHA can significantly improve an expression level of neurotrophic factors and protect and repaire a nervous system. (Figl)

This invention belongs to the field of cosmetic technology and discloses a composition containing polypeptides, its preparation method, and its application. The composition provided by this invention comprises: polypeptides and a solubilizing and penetration-enhancing complex; the polypeptides include at least one selected from Codonopsis pilosula cyclic peptide B, conopeptide, carnosine, acetyl tetrapeptide-5, acetyl hexapeptide-8, and nonapeptide-1; the solubilizing and penetration-enhancing complex comprises the fermentation product filtrate of Kluyveromyces lactis / Ganoderma lucidum fruiting body extract, polyols, polysorbate, and ferulic acid. The composition provided by this invention, through the synergistic effect between its components, can effectively improve the solubility and stability of the polypeptides, preventing precipitation or exudation, while effectively promoting the transdermal absorption of the polypeptides; the composition provided by this invention has excellent antioxidant and anti-aging effects.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

This invention relates to the field of antibodies, and more particularly to TAT antibodies and their applications. The invention provides coated antibodies comprising a heavy chain variable region and a light chain variable region, wherein: the CDR1, CDR2, and CDR3 regions of the heavy chain variable region have amino acid sequences as shown in SEQ ID No:1 to SEQ ID No:3; and the CDR1, CDR2, and CDR3 regions of the light chain variable region have amino acid sequences as shown in SEQ ID No:4 to SEQ ID No:6. This invention successfully prepared highly specific monoclonal antibodies 7E10 and 2B4 against the thrombin-antithrombin III complex (TAT), wherein 7E10 specifically binds to thrombin (THR), and 2B4 specifically binds to antithrombin III (AT-III). Using these two antibodies in combination enables highly sensitive and specific detection of the TAT complex.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.